[AERI] Aerie Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 38.65 Change: 1.45 (3.9%)
Ext. hours: Change: 0 (0%)

chart AERI

Refresh chart

Strongest Trends Summary For AERI

AERI is in the medium-term down -21% below S&P in 3 months and down -37% below S&P in 1 year. In the long-term up 305% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.

Fundamental Ratios
Shares Outstanding EPS-3.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-15.12
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-30.07% ROE-120.74% ROI
Current Ratio7.63 Quick Ratio Long Term Debt/Equity Debt Ratio0.46
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities35.07 M Cash From Investing Activities6.1 M Cash From Operating Activities-13.31 M Gross Profit
Net Profit-17.24 M Operating Profit-19.64 M Total Assets195.2 M Total Current Assets170.96 M
Total Current Liabilities22.39 M Total Debt124.19 M Total Liabilities146.58 M Total Revenue
Technical Data
High 52 week73.9 Low 52 week33 Last close39.06 Last change-3.65%
RSI49.1 Average true range2.31 Beta1.37 Volume623.98 K
Simple moving average 20 days-1.74% Simple moving average 50 days-9.69% Simple moving average 200 days-19%
Performance Data
Performance Week-9.21% Performance Month-1.81% Performance Quart-6.44% Performance Half-9.83%
Performance Year-23.71% Performance Year-to-date8.2% Volatility daily3.7% Volatility weekly8.26%
Volatility monthly16.94% Volatility yearly58.67% Relative Volume235.1% Average Volume664.56 K
New High New Low

News

2019-06-18 08:05:56 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-06-17 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

2019-06-13 08:03:28 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-06-11 08:04:17 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-06-11 07:30:00 | Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

2019-06-10 08:05:36 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-06-06 13:58:01 | Does Aerie Pharmaceuticals, Inc. NASDAQ:AERI Have A Particularly Volatile Share Price?

2019-06-06 09:31:01 | Why Is Aerie AERI Down 10.2% Since Last Earnings Report?

2019-06-06 08:06:55 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-05-28 07:30:00 | Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

2019-05-21 17:36:09 | Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

2019-05-08 14:45:06 | Aerie AERI Q1 Earnings Beat, Rhopressa Misses Estimates

2019-05-08 00:02:38 | Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT

2019-05-07 22:46:35 | Aerie Pharmaceuticals, Inc. AERI Q1 2019 Earnings Call Transcript

2019-05-07 18:15:10 | Aerie Pharmaceuticals AERI Reports Q1 Loss, Lags Revenue Estimates

2019-05-07 17:09:37 | Aerie: 1Q Earnings Snapshot

2019-05-07 16:01:00 | Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-07 08:05:55 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-05-03 14:42:30 | Another $100 million 'safety net' set for this Triangle pharma

2019-05-02 18:33:00 | Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M

2019-05-02 12:42:44 | Here’s What Hedge Funds Think About Aerie Pharmaceuticals Inc AERI

2019-05-01 12:00:00 | With profits in sight, Durham pharma launches new trials

2019-05-01 06:30:00 | Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives

2019-04-30 08:05:49 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-04-30 07:30:00 | Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019

2019-04-25 06:30:00 | Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant

2019-04-11 10:05:00 | Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

2019-04-10 12:05:55 | Have Insiders Been Selling Aerie Pharmaceuticals, Inc. NASDAQ:AERI Shares This Year?

2019-04-02 07:30:00 | Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

2019-04-01 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe

2019-03-28 17:07:09 | Aerie AERI Improves 22% YTD: Is Momentum Likely to Sustain?

2019-03-27 09:30:01 | Aerie AERI Down 2.9% Since Last Earnings Report: Can It Rebound?

2019-03-25 06:30:00 | Aerie Pharmaceuticals Announces Four Appointments

2019-03-22 11:23:03 | Aerie AERI Starts Phase II Study on Eye Candidate in Japan

2019-03-21 06:30:00 | Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing

2019-03-19 12:28:04 | Aerie AERI Starts Phase II Study on Eye Candidate AR-1105

2019-03-18 06:30:00 | Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 Dexamethasone Intravitreal Implant in Patients with Macular Edema Associated with Retinal Vein Occlusion

2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma

2019-03-13 07:27:36 | The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

2019-03-12 18:30:00 | Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance

2019-03-12 18:20:00 | Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ netarsudil and latanoprost ophthalmic solution 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

2019-03-07 08:13:36 | Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years

2019-03-05 08:02:09 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-03-05 07:30:00 | Aerie Pharmaceuticals to Present at Two Investor Conferences in March

2019-03-01 08:25:00 | New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-02-26 20:40:37 | Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT

2019-02-26 10:34:03 | Aerie AERI Q4 Earnings Miss, Rhopressa Gains Traction

2019-02-25 21:13:52 | Aerie Pharmaceuticals Inc AERI Q4 2018 Earnings Conference Call Transcript

2019-02-25 16:01:00 | Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update

2019-02-22 13:55:45 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs